Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) has granted CheckPoint Immunology Inc. (a wholly-owned subsidiary of the Company) an exclusive worldwide license to develop and commercialize Regen’s NR2F6 technology for human therapeutic use. The objective of the license grant is the separation of Regen’s small molecule technology from its other intellectual property in order to facilitate any future transactions involving small molecule therapies focused on the NR2F6 checkpoint.